Lopinavir (ABT-378) + Ritonavir + Stavudine + Lamivudine

M97-720 Trial

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve
M97-720: Study Design

Study Design: M97-720

- **Background**: Prospective, randomized, double-blind phase I/II study to evaluate the safety and efficacy of various doses of lopinavir and ritonavir in combination with stavudine and lamivudine in treatment-naïve patients with HIV infection
- **Inclusion Criteria (n = 100)**
  - Age ≥18
  - Antiretroviral-naïve
  - HIV RNA >5000 copies/mL
- **Treatment Arms**
  - Lopinavir-ritonavir 200/100 mg BID or 400/100 mg BID x 3 weeks, then with stavudine + lamivudine BID
  - Lopinavir-ritonavir 400/100 mg BID or 400/200 mg BID + stavudine + lamivudine
  - After 48 weeks, lopinavir-ritonavir dosed open-label at 400/100 mg BID + stavudine + lamivudine

Group I
LPV/r 200/100 mg BID or 400/100 mg BID, + d4t/3TC added at week 3
(n = 32)

Group II
LPV/r 400/100 mg BID or 400/200 mg BID, + d4T/3TC
(n = 68)

Source: Murphy RL, et al. AIDS. 2001;15:F1-9.

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve
M97-720: Results

Week 48: Virologic Response (ITT, Missing=Failure), overall group results



Source: Murphy RL, et al. AIDS. 2001;15:F1-9.

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve
M97-720: Results

Week 48: Virologic Response (ITT, M=F), by ABT-378 dose arm



Source: Murphy RL, et al. AIDS. 2001;15:F1-9.

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve M97-720: Results

Most Common Adverse Events (occurring in ≥ 5% of patients overall by week 48)				
Adverse event	**Group I: LPV-RTV 200/100mg BID** (n = 16)	**Group I: LPV-RTV 400/100mg BID** (n = 16)	**Group II: LPV-RTV 400/100mg BID** (n=35)	**Group II: LPV-RTV 400/200mg BID** (n=33)
Nausea	13%	0%	9%	30%
Diarrhea	13%	25%	17%	24%
Abnormal stools	19%	19%	6%	0%
Vomiting	6%	0%	0%	12%
Asthenia	6%	13%	6%	6%
Headache	6%	13%	6%	6%
Triglycerides (>750mg/dL)	19%	6%	6%	15%
Total cholesterol (>300mg/dL)	13%	6%	6%	15%
AST or ALT > 5x ULN	0%	0%	20%	3%

Source: Murphy RL, et al. AIDS. 2001;15:F1-9.

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve
M97-720: Conclusions

Conclusions: "ABT-378 is a potent, well-tolerated protease inhibitor. The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations."

Source: Murphy RL, et al. AIDS. 2001;15:F1-9.

Lopinavir (ABT-378) + Ritonavir + NRTIs in Treatment-Naïve
M97-720: Results at 4-year Follow-up

Week 204: Virologic Response (ITT, Missing=Failure)



Source: Hicks C, et al. AIDS. 2004;18:775-9.

National HIV Curriculum

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

National HIV Curriculum

AETC AIDS Education & Training Center Program
National Coordinating Resource Center